Source:http://linkedlifedata.com/resource/pubmed/id/15501061
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
23
|
| pubmed:dateCreated |
2004-10-25
|
| pubmed:abstractText |
A series of tetrahydroisoquinolines has yielded potent MT(2) receptor antagonists, which are selective versus the MT(1) receptor.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Dec
|
| pubmed:issn |
0960-894X
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:day |
6
|
| pubmed:volume |
14
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
5881-4
|
| pubmed:meshHeading | |
| pubmed:year |
2004
|
| pubmed:articleTitle |
Tetrahydroisoquinoline derivatives as melatonin MT2 receptor antagonists.
|
| pubmed:affiliation |
Bristol-Myers Squibb Pharmaceutical Research Institute, Wallingford, CT 06492-7660, USA. karageog@bms.com
|
| pubmed:publicationType |
Journal Article
|